VEGFxPD-(L)1 Multispecifics Report
Following the release of standout data for ivonescimab and surge in recent deals between major biopharma such as Summit Therapeutics and Pfizer clinical collaboration, we have analysed the emergence of VEGFxPD-(L)1 multispecifics.
With exclusive data from Beacon, this review contains:
- Insights into the potential of VEGFxPD-(L)1 multispecifics becoming the new standard of care in lung cancer
- Analysis of the combination therapies that are being evaluated in VEGFxPD-(L)1 clinical trials
- An overview of the VEGFxPD-(L)1 licensing deals between major biopharma companies
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
